Login to Your Account

$75M Up Front, Potential $425M Later

Xencor Signs Amgen in Option Deal in Autoimmune Diseases

By Jennifer Boggs

Monday, January 10, 2011
About six months after inking a collaboration with MorphoSys AG for a Phase I-ready cancer candidate, antibody engineering firm Xencor Inc. signed an option deal with Thousand Oaks, Calif.-based Amgen Inc. targeting the autoimmune space.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription